naporafenib,Trametinib,Ribociclib,Rineterkib
novartis
['melanoma', 'napora']
for metastatic braf and nras mutated melanomas progressing on standard therapies, naporafenib (braf and craf inhibitor) shows orr 21% in heavily nrasm melanoma and no objective responses in brafm melanoma dcr for nrasm melanoma is higher than 60% #esmo22 #melanoma 
Medical Oncologist. Melanoma and Skin Tumors. Early phase and phase III clinical trials. Hospital Clínic (Barcelona). Opinions are mine.